Literature DB >> 12614300

Review article: gastric acidity--comparison of esomeprazole with other proton pump inhibitors.

J G Hatlebakk1.   

Abstract

Gastric acid suppression is the most effective medical therapy to control acidic gastro-oesophageal reflux: individuals in whom therapy fails usually have inadequate acid suppression. Twenty-four-hour intragastric pH-metry measures the percentage of time that gastric pH is above 4 or 3, the critical thresholds for tissue damage and symptom generation in the distal oesophagus. Effective medical therapy must control gastric acidity throughout the daytime, including the postprandial period. It is therefore useful to report the percentage of patients in whom gastric acidity is controlled above pH 4 for at least 16 out of 24 h. Esomeprazole was compared with standard-dose proton pump inhibitors in healthy volunteers and patients with gastro-oesophageal reflux disease. Esomeprazole, 40 mg daily, was significantly more effective at controlling gastric acidity above pH 4 for more than 16 h than lansoprazole, 30 mg daily (38% of individuals vs. 5%, respectively). Esomeprazole, 40 mg daily, also suppressed gastric acidity more effectively and in more individuals than pantoprazole, 40 mg daily, and rabeprazole, 20 mg daily. Esomeprazole, 20 mg daily, was significantly more effective at controlling gastric acidity than lansoprazole, 15 mg daily. The improved acid control with esomeprazole compared with other proton pump inhibitors is likely to result in superior healing rates and improved symptom relief, with fewer therapy-resistant patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614300     DOI: 10.1046/j.1365-2036.17.s1.3.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

Review 1.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Comparison of esomeprazole enteric-coated capsules vs esomeprazole magnesium in the treatment of active duodenal ulcer: a randomized, double-blind, controlled study.

Authors:  Xiao-Yan Liang; Qing Gao; Neng-Ping Gong; Li-Ping Tang; Pi-Long Wang; Xiao-Hong Tao
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

3.  The anti-secretory and anti-ulcer activities of esomeprazole in comparison with omeprazole in the stomach of rats and rabbits.

Authors:  Salim M A Bastaki; Irwin S Chandranath; Jaipaul Singh
Journal:  Mol Cell Biochem       Date:  2007-11-28       Impact factor: 3.396

4.  Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.

Authors:  David Y Graham; Aylin Tansel
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-28       Impact factor: 11.382

5.  Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants.

Authors:  Huiping Xu; Melissa O'Gorman; Kyle Matschke; Tanya Boutros; Nicoletta Brega; Weiwei Tan; Akintunde Bello
Journal:  Clin Pharmacol Drug Dev       Date:  2021-11-26

Review 6.  The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease.

Authors:  Anita Gąsiorowska
Journal:  Prz Gastroenterol       Date:  2017-12-14

7.  A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications.

Authors:  Divya Patel; Richard Bertz; Song Ren; David W Boulton; Mats Någård
Journal:  Clin Pharmacokinet       Date:  2020-04       Impact factor: 6.447

8.  A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).

Authors:  Evangelos Kalaitzakis; Einar Björnsson
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

9.  Evaluation of potential drug interactions with sodium zirconium cyclosilicate: a single-center, open-label, one sequence crossover study in healthy adults.

Authors:  Mats Någård; William G Kramer; David W Boulton
Journal:  Clin Kidney J       Date:  2020-12-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.